Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
about
PSA and beyond: alternative prostate cancer biomarkersA prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressivenessBenign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men.[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening studyBiomarkers in prostate cancer surveillance and screening: past, present, and future.A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.Biomarkers for prostate cancer detection.From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.Prostate-specific antigen-based prostate cancer screening: Past and future.Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.Significance of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia in prostate biopsy.Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.
P2860
Q26770646-04219629-6D0B-4E48-9CD1-FFC364CE7709Q33839248-C0E3877E-D0BF-447A-9447-12195B58DDA9Q35838386-8E74E03E-34F5-4033-88F6-4AE741645AFBQ36509148-B12142CC-C88F-4217-8086-C18D1B026318Q37300931-7E179C24-D2FD-4CD9-862E-928C2B0F545AQ37507776-49A0BF0A-CCB3-449B-981D-AED194DE90D9Q37656233-1A1C9B16-A490-4693-98C2-9574BA77394EQ38023597-B589D37B-7985-4635-813B-631C49707EC8Q38408501-C821C612-2F07-490A-9A51-777AA8636E3AQ39885547-77E222C9-A614-4A8B-A9A7-998094D8A15DQ39921715-C9E2FD47-0463-47DF-B534-94E11B673E17Q53598540-F4367376-4801-4DAD-896E-0A833AA7EED8
P2860
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
@en
type
label
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
@en
prefLabel
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
@en
P2093
P1433
P1476
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
@en
P2093
Cindy L Evans
Daniel W Chan
Harry G Rittenhouse
Harry J Linton
Leslie A Mangold
Lori J Sokoll
Masood A Khan
Phaedre Mohr
Stephen D Mikolajczyk
P304
P356
10.1016/J.UROLOGY.2004.06.033
P407
P577
2004-12-01T00:00:00Z